Baseline data in the study on the tolerance and efficacy of peripheral defocus spectacles for the control of myopia progression in Argentina (Myofix Defocus Study)
DOI:
https://doi.org/10.70313/2718.7446.v17.n03.350Keywords:
peripheral defocus spectacle, control of myopia, novel designAbstract
Purpose: To evaluate the efficacy and tolerability of the use of a new model of spectacles designed to control the progression of myopia in childhood.
Methods: The Myofix Defocus Study is a longitudinal, prospective, interventional, non-randomized research study for myopia control spectacles. This field study includes 48 myopic children aged 8 to 15 years old without other ocular pathology, enrolled from June 2023 to April 2024. In this study, patients were offered the option of undergoing a treatment accessible in our region (compounded diluted atropine drops) or a possibly equally effective treatment with special glasses designed in our country. In the present study, a complete initial ophthalmological evaluation with objective refraction under cycloplegia was performed, with recording of axial length measurements and a survey on habits, lifestyle and family history of high myopia.
Initial data showed a mean age of 10.72 ± 2.48 years and that 23/48 of them were girls. Their mean spherical equivalent was -2.61 ± 1.12 dioptres in the right eye and -2.37 ± 1.12 dioptres in the left eye. The mean keratometry was 43.52 ± 1.32 dioptres in the right and left eye. The average axial length was 24.38 ± 0.79 mm for the right eye and 24.34 ± 0.79 mm for the left eye.
Conclusion: The initial data of the Myofix Defocus Study comprise a sample of myopic schoolchildren prone to progressive myopia according to their mean age.
Downloads
References
Rudnicka AR, Kapetanakis VV, Wathern AK et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol 2016; 100: 882-890.
Holden BA, Fricke TR, Wilson DA et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016; 123: 1036-1042.
Kim EC, Morgan IG, Kakizaki H et al. Prevalence and risk factors for refractive errors: Korean National Health and Nutrition Examination Survey 2008-2011. PLoS One 2013; 8: e80361.
Dolgin E. The myopia boom. Nature 2015; 519: 276-278.
Schellini SA, Durkin SR, Hoyama E et al. Prevalence of refractive errors in a Brazilian population: the Botucatu eye study. Ophthalmic Epidemiol 2009; 16: 90-97.
Ohno-Matsui K, Wu PC, Yamashiro K et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci 2021; 62: 5.
Sankaridurg P, Tahhan N, Kandel H et al. IMI impact of myopia. Invest Ophthalmol Vis Sci 2021; 62: 2.
Wildsoet CF, Chia A, Cho P et al. IMI - Interventions Myopia Institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci 2019; 60: M106-M131.
Galan MM SA, Fernandez Irigaray L, Rodriguez G, Aguirre R, Kotlik C, Iribarren R. Consensus on progressive myopia management. Oftalmol Clin Exp 2022; 15: e137-e156. Available at: https://revistaoce.com/index.php/revista/article/view/160/247.
Kesarwani SS, Mumbai Group of Paediatric Ophthalmologists and Strabismologists. Consensus statement and guidelines for use of dilute atropine sulphate in myopia control. Indian J Ophthalmol 2019; 67: 461-463.
World Society of Paediatric Ophthalmology & Strabismus (WSPOS). Myopia consensus statement 2023. London: WSPOS, 2023. Available at: https://wspos.org/swdcore/uploads/WSPOS-Myopia-Consensus-Statement-2023-1.pdf
Charman WN, Radhakrishnan H. Peripheral refraction and the development of refractive error: a review. Ophthalmic Physiol Opt 2010; 30: 321-338.
De Tomas M, Kotlik C, Szeps A et al. New spectacles for myopia control. Oftalmol Clin Exp 2022; 15: e244-e247.
Picotti C, Sánchez V, Fernández Irigaray L et al. Myopia progression in children during COVID-19 home confinement in Argentina. Oftalmol Clin Exp 2021; 14(3): 156-161. Available at: https://revistaoce.com/index.php/revista/article/download/73/107
Repka MX, Weise KK, Pediatric Eye Disease Investigator Group et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol 2023; 141: 756-765.
Lam CSY, Tang WC, Tse DY et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol 2020; 104: 363-368.
De Tomas M, Szeps A, Martín G et al. Retinal shadows produced by myopia control spectacles. Ophthalmic Physiol Opt 2024; 44: 214-218.
Panorgias A, Aigbe S, Jeong E et al. Retinal responses to simulated optical blur using a novel dead leaves ERG stimulus. Invest Ophthalmol Vis Sci 2021; 62: 1.
Read SA, Collins MJ, Sander BP. Human optical axial length and defocus. Invest Ophthalmol Vis Sci 2010; 51: 6262-6269.
Iribarren R, Szeps A, Kotlik C et al. Short-term axial length changes in myopic eyes induced by defocus spectacles for myopia control. Photonics 2023; 10: 668.
Bullimore MA, Brennan NA. Myopia: an ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt 2023; 43: 116-121.
Fernández Irigaray L, Balsa A, Armesto A et al. Outdoor exposure in children from Buenos Aires Province, Argentina. Arch Soc Esp Oftalmol (Engl Ed) 2022; 97: 396-406.
Published
Issue
Section
License
Copyright (c) 2024 Consejo Argentino de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Con esta licencia no se permite un uso comercial de la obra original, ni la generación de obras derivadas. Las licencias Creative Commons permiten a los autores compartir y liberar sus obras en forma legal y segura.
How to Cite
